检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王清华[1] 窦常胜[1] 顾勇[1] 金玉凤[1] 刘丽[1]
机构地区:[1]皖南医学院附属弋矶山医院儿科,安徽芜湖241001
出 处:《皖南医学院学报》2015年第1期33-35,共3页Journal of Wannan Medical College
摘 要:目的:通过观察不同组别川崎病(KD)患儿血浆内皮素(ET)、一氧化氮(NO)的水平变化,探讨其临床价值以及与冠状动脉损伤(CALs)的关系。方法:对住院KD患儿常规行心脏超声检查,根据结果分为CALs组(30例)和无CALs组(50例),另选取90例年龄、性别无明显统计差异的同期门诊体检健康儿童作为正常对照组,同时选取同期住院的肺炎患儿40例作为病例对照组。分别采用放射性免疫方法、硝酸还原酶法测得各组血浆ET、NO水平。结果:KD患儿急性期血浆ET、NO均高于正常对照组和病例对照组,差异有统计学意义,治疗后则较正常组无明显统计学差异;CALs组血浆ET、NO均高于NCALs组,P<0.001。结论:KD患儿ET、NO的水平明显增加,且ET、NO的水平可能与冠脉损伤有关。Objective: To investigate the level changes of plasmic endothelin( ET) and nitric oxide( NO) in children with Kawasaki disease( KD) for determination of the clinical values of the changes and coronary artery lesions( CALs). Methods: By the routine echocardiographic findings,the hospitalized KD children were allocated to group with CALs( n = 30) and without CALs( n = 50). Ninety healthy subjects( without significant difference in ages and genders) undergone physical examination on out-patient basis were included as healthy controls and another 40 inpatient children with pneumonia undergone treatment on hospital stay basis were recruited as case controls. Radioimmunoassay and nitrate reductase methods were used to measure the plasma ET and NO levels in each group described above. Results: Higher plasma levels of ET and NO were seen in KD children in their acute stage than the healthy controls and case controls,and the difference was significant,whereas the difference was not after treatment as compared with the healthy controls. Plasma ET and NO levels were higher in children with CALs than those without CALs( P〈0. 001). Conclusion: Plasma levels of ET and NO tend to significantly elevate in KD children,suggesting that changes of ET and NO levels may be associated with coronary artery lesion.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.80